Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rational design of small molecules able to inhibit α-synuclein amyloid aggregation for the treatment of Parkinson’s disease

1 Jan 2020

Abstract excerpt

Parkinson’s disease is one of the most common neurodegenerative disorders in elderly age. One of the mechanisms involved in the neurodegeneration appears related to the aggregation of the presynaptic protein alpha synuclein (α-syn) into toxic oligomers and fibrils. To date, no highly effective treatment is currently available; therefore, there is an increasing interest in the search of new therapeutic tools. The...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer's disease research and treatments
Share to Click Chemistry and Applications
Share to Parkinson's Disease Mechanisms and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 32924648
DOI: 10.1080/14756366.2020.1816999

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rational design of small molecules able to inhibit α-synuclein amyloid aggregation for the treatment of Parkinson’s diseasePMID 32924648Read ↗

Curcumin Pyrazole and its derivative (N-(3-Nitrophenylpyrazole) Curcumin inhibit aggregation, disrupt fibrils and modulate toxicity of Wild type and Mutant α-Synuclein.Semantic proximity Read ↗

Small-Molecule Amyloid Beta-Aggregation Inhibitors in Alzheimer's Disease Drug DevelopmentSemantic proximity Read ↗

In Silico, in Vitro, and in Vivo Evaluation of New Candidates for α-Synuclein PET ImagingSemantic proximity Read ↗

Therapeutic potential of methylxanthine drug on alpha synuclein protein in Parkinson’s diseaseSemantic proximity Read ↗

Modulating the Amyloidogenesis of α-Synuclein.Semantic proximity Read ↗

The good and bad of therapeutic strategies that directly target α‐synucleinSemantic proximity Read ↗

Peptide ligand screening of α-synuclein aggregation modulators by in silico panningSemantic proximity Read ↗

Protein mimetic 2D FAST rescues alpha synuclein aggregation mediated early and post disease Parkinson's phenotypes.Semantic proximity Read ↗

Inhibition of α-synuclein aggregation by MT101-5 is neuroprotective in mouse models of Parkinson’s diseaseSemantic proximity Read ↗

Structure-based discovery of small molecule inhibitors of the autocatalytic proliferation of α-synuclein aggregatesSemantic proximity Read ↗

Identification of Bile Acid-Derived Chemical Chaperone(s) Targeting E46K-Mutated Alpha-Synuclein Protein to Treat Parkinson's Disease: Molecular Modelling, Docking, ADME, and Simulation Studies.Semantic proximity Read ↗

A <i>de novo</i> compound targeting α-synuclein improves deficits in models of Parkinson's diseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.